Straumann Holding AG

BATS-CHIXE:STMNZ Stock Report

Market Cap: CHF 17.8b

Straumann Holding Valuation

Is STMNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STMNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: STMNZ (CHF111.3) is trading above our estimate of fair value (CHF109.64)

Significantly Below Fair Value: STMNZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STMNZ?

Key metric: As STMNZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for STMNZ. This is calculated by dividing STMNZ's market cap by their current earnings.
What is STMNZ's PE Ratio?
PE Ratio61.8x
EarningsCHF 287.88m
Market CapCHF 17.78b

Price to Earnings Ratio vs Peers

How does STMNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for STMNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.6x
SN. Smith & Nephew
35.4x22.5%UK£8.6b
NIOX NIOX Group
23.2x17.1%UK£255.5m
CTEC ConvaTec Group
39.5x20.5%UK£4.8b
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
STMNZ Straumann Holding
61.8x20.9%CHF 17.8b

Price-To-Earnings vs Peers: STMNZ is expensive based on its Price-To-Earnings Ratio (61.8x) compared to the peer average (30.6x).

Price to Earnings Ratio vs Industry

How does STMNZ's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: STMNZ is expensive based on its Price-To-Earnings Ratio (61.8x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is STMNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STMNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.8x
Fair PE Ratio46.3x

Price-To-Earnings vs Fair Ratio: STMNZ is expensive based on its Price-To-Earnings Ratio (61.8x) compared to the estimated Fair Price-To-Earnings Ratio (46.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STMNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 111.30
CHF 131.12
+17.8%
17.3%CHF 175.00CHF 90.00n/a17
Nov ’25CHF 116.25
CHF 133.82
+15.1%
16.3%CHF 175.00CHF 90.00n/a17
Oct ’25CHF 137.55
CHF 137.06
-0.4%
16.4%CHF 175.00CHF 90.00n/a18
Sep ’25CHF 126.10
CHF 134.83
+6.9%
16.9%CHF 175.00CHF 90.00n/a18
Aug ’25CHF 113.20
CHF 134.33
+18.7%
18.1%CHF 175.00CHF 90.00n/a18
Jul ’25CHF 113.05
CHF 134.39
+18.9%
18.4%CHF 175.00CHF 90.00n/a18
Jun ’25CHF 117.35
CHF 135.94
+15.8%
18.2%CHF 175.00CHF 90.00n/a18
May ’25CHF 124.75
CHF 138.67
+11.2%
18.4%CHF 175.00CHF 90.00n/a18
Apr ’25CHF 144.00
CHF 142.32
-1.2%
18.4%CHF 175.00CHF 90.00n/a19
Mar ’25CHF 143.00
CHF 134.22
-6.1%
17.7%CHF 168.00CHF 90.00n/a18
Feb ’25CHF 137.30
CHF 128.22
-6.6%
16.1%CHF 153.00CHF 90.00n/a18
Jan ’25CHF 135.50
CHF 125.41
-7.4%
15.2%CHF 150.00CHF 90.00n/a17
Dec ’24CHF 119.85
CHF 124.47
+3.9%
14.8%CHF 150.00CHF 90.00n/a17
Nov ’24CHF 105.50
CHF 131.99
+25.1%
16.8%CHF 167.00CHF 90.00CHF 116.2517
Oct ’24CHF 117.00
CHF 135.38
+15.7%
18.0%CHF 167.00CHF 90.00CHF 137.5516
Sep ’24CHF 134.00
CHF 136.82
+2.1%
17.7%CHF 167.00CHF 90.00CHF 126.1017
Aug ’24CHF 143.90
CHF 134.47
-6.6%
20.4%CHF 165.00CHF 82.00CHF 113.2017
Jul ’24CHF 145.40
CHF 133.76
-8.0%
21.1%CHF 165.00CHF 82.00CHF 113.0517
Jun ’24CHF 134.85
CHF 131.88
-2.2%
22.3%CHF 165.00CHF 82.00CHF 117.3516
May ’24CHF 133.90
CHF 124.87
-6.7%
21.4%CHF 160.00CHF 82.00CHF 124.7515
Apr ’24CHF 136.10
CHF 124.53
-8.5%
21.8%CHF 160.00CHF 82.00CHF 144.0015
Mar ’24CHF 124.25
CHF 120.43
-3.1%
21.2%CHF 158.00CHF 80.00CHF 143.0014
Feb ’24CHF 121.30
CHF 116.21
-4.2%
20.4%CHF 150.00CHF 80.00CHF 137.3014
Jan ’24CHF 106.05
CHF 119.00
+12.2%
18.7%CHF 150.00CHF 88.00CHF 135.5013
Dec ’23CHF 108.15
CHF 122.08
+12.9%
17.9%CHF 153.00CHF 90.00CHF 119.8512
Nov ’23CHF 95.32
CHF 129.29
+35.6%
23.9%CHF 205.00CHF 90.00CHF 105.5013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

-0.06%

1Y

-16.0%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

5.2%

1Y

-18.4%

Kooth

UK£60.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.65

7D

1.5%

1Y

-45.2%